Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements
- PMID: 38956913
- DOI: 10.2174/0118715273306577240612053957
Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements
Abstract
Background: Gliomas are the most frequent, heterogeneous group of tumors arising from glial cells, characterized by difficult monitoring, poor prognosis, and fatality. Tissue biopsy is an established procedure for tumor cell sampling that aids diagnosis, tumor grading, and prediction of prognosis.
Materials and methods: We studied and compared the levels of liquid biopsy markers in patients with different grades of glioma. Also, we tried to prove the potential association between glioma and specific blood group antigens.
Results: 78 patients were found, among whom the maximum percentage with glioblastoma had blood group O+ (53.8%). The second highest frequency had blood group A+ (20.4%), followed by B+ (9.0%) and A- (5.1%), and the least with O-. Liquid biopsy biomarkers included Alanine Aminotransferase (ALT), Lactate Dehydrogenase (LDH), lymphocytes, Urea, Alkaline phosphatase (AST), Neutrophils, and C-Reactive Protein (CRP). The levels of all the components increased significantly with the severity of the glioma, with maximum levels seen in glioblastoma (grade IV), followed by grade III and grade II, respectively.
Conclusion: Gliomas have significant clinical challenges due to their progression with heterogeneous nature and aggressive behavior. A liquid biopsy is a non-invasive approach that aids in setting up the status of the patient and figuring out the tumor grade; therefore, it may show diagnostic and prognostic utility. Additionally, our study provides evidence to prove the role of ABO blood group antigens in the development of glioma. However, future clinical research on liquid biopsy will improve the sensitivity and specificity of these tests and confirm their clinical usefulness to guide treatment approaches.
Keywords: CRP; LFT; Liquid biopsy; blood group; correlations.; glioma; stages; trends.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.Dan Med J. 2014 Oct;61(10):B4944. Dan Med J. 2014. PMID: 25283629
-
The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.Brain Tumor Pathol. 2019 Apr;36(2):29-39. doi: 10.1007/s10014-019-00335-0. Epub 2019 Mar 11. Brain Tumor Pathol. 2019. PMID: 30859343 Review.
-
Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.Int J Mol Sci. 2024 Jul 21;25(14):7974. doi: 10.3390/ijms25147974. Int J Mol Sci. 2024. PMID: 39063215 Free PMC article. Review.
-
Beyond the blood-brain barrier: feasibility and technical validation of dual-compartment circulating tumor cells detection in high-grade glioma patients.Neurosurg Rev. 2025 Apr 11;48(1):359. doi: 10.1007/s10143-025-03511-3. Neurosurg Rev. 2025. PMID: 40214852 Free PMC article.
-
Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.Front Immunol. 2022 Jan 7;12:809826. doi: 10.3389/fimmu.2021.809826. eCollection 2021. Front Immunol. 2022. PMID: 35069595 Free PMC article.
References
-
- Wang L.M.; Human brain and spinal cord tumors: From bench to bedside. In: The Path to Bedside Management 2023,2,1-30
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous